title: [A preliminary study of the administration of carbapenem antibiotics in sepsis patients on the basis of the administration time].
abstract: It is important to take into consideration the duration for which the plasma concentration of the drug is higher than the Minimal Inhibitory Concentration during treatment with carbapenem antibiotics, because the antibiotics are time-dependent drugs. A preliminary study of the administration of carbapenem antibiotics on the basis of the pharmacokinetics/pharmacodynamics (PK/PD) was conducted.
  
  
  METHODS
  Ten patients with intraabdominal infection.
  
  
  METHODS
  The patients were divided into two groups: the first group was assigned to administration of a carbapenem antibiotic (meropenem) at a daily dose of 0.5 g in 3 divided doses, each dose by intravenous infusion over 3 hours (Group 3 H), and the other group was assigned to administration of each dose over 30 minutes (Group 30 M). The body temperature (BT), white blood cell count (WBC), serum C-reactive protein (CRP) level, and the systemic inflammatory reactive syndrome (SIRS) score before and 96 hours after the drug administration were compared between Group 3 H and Group 30 M.
  
  
  RESULTS
  There were 5 patients (mean age, 67.4+/-14.6 years) in Group 3H and 5 patients (mean age, 60.0+/-12.8 years) in Group 30 M. The evaluated parameters (BT, WBC, CRP, SIRS score) before the drug administration in Groups 3 H and 30M were not significant. Group 3 H showed significant decreases in the SIRS scores at 96 hours after the drug administration, however, there were no significant differences in the BT, WBC or CRP between the two groups.
  
  
  CONCLUSIONS
  Group 3 H showed early improvement in the SIRS scores. Administration of carbapenem antibiotics based on the PK/PD is important, and requires further studies.
authors.affiliation: Department of Critical Care Medicine, Iwate Medical University.
authors.forename: Masahiro
authors.initials: M
authors.lastname: Kojika
authors.forename: Nobuhiro
authors.initials: N
authors.lastname: Sato
authors.forename: Masanori
authors.initials: M
authors.lastname: Hakozaki
authors.forename: Yasusi
authors.initials: Y
authors.lastname: Suzuki
authors.forename: Gaku
authors.initials: G
authors.lastname: Takahasi
authors.forename: Sigeatu
authors.initials: S
authors.lastname: Endo
authors.forename: Kenji
authors.initials: K
authors.lastname: Suzuki
authors.forename: Go
authors.initials: G
authors.lastname: Wakabayasi
mesh_terms: D000005:Abdomen / Q000382:microbiology; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000900:Anti-Bacterial Agents / Q000008:administration & dosage* / Q000493:pharmacokinetics; D001202:Ascitic Fluid / Q000382:microbiology; D016470:Bacteremia / Q000188:drug therapy* / Q000378:metabolism / Q000382:microbiology; D015780:Carbapenems / Q000008:administration & dosage* / Q000493:pharmacokinetics; D004334:Drug Administration Schedule; D005260:Female; D006801:Humans; D008297:Male; D000077731:Meropenem; D008875:Middle Aged; D013845:Thienamycins / Q000008:administration & dosage* / Q000493:pharmacokinetics
chemical_list: D000900:Anti-Bacterial Agents; D015780:Carbapenems; D013845:Thienamycins; D000077731:Meropenem